Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 08, 2021 4:22pm
161 Views
Post# 32745530

RE:RE:RE:RE:AACR Presentation is important

RE:RE:RE:RE:AACR Presentation is importantYou can count on it! I will also calculate the millions lost by shareholders by the deal being done at such a low price which gave no credit for the stuff TH will then be getting $240 a share for!

I have very few things that get me bent permanently out of shape, but dumb deals are one of them.

realitycheck4u wrote:

I am Imagining in the future a post like this from SPCEO.

"What an incredible offer to purchase the company at $240 a share, but it's only two bad that the previous share offering was done way back at sub three dollars when they should have waited until a few more weeks before doing it because the stock price would've been much higher"


 

SPCEO1 wrote: While I will likely always view the odious offering as a disaster on a number of levels, I don't think you should read any pessimism from that seeping into the last post of mine. I didn't think it was pessimistic, just a straightforward look at the potential catalysts, or lack thereof, in the short term. Not pessimistic, not optimistic, just realistic. That was a forward looking post, not a backward looking one. And I think the stock has huge upside potential despite the odious offering. So, I am an optimist about TH's share price prospects. If they get serious about marketing the stock, others should be able to easily see the potential as well.

 

FredTheVoice wrote: I have lots of respect for you SPCEO, but naturally, what I am hearing is the continuity of the grief process......

There is something like a pessimism in your messages now.....

I understand, but,

It looks more possible to me that NASH protocol will be clarified within the next few weeks, you dont get that GO letter from the FDA, and than no news for three months, dont think so......

Lets see.

FTV.

 




<< Previous
Bullboard Posts
Next >>